← Leaderboards
David J. Vaughn
University Of Pennsylvania
$3,040,933
Attributed
$3,040,933
Total exposure
6
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $506.2K · FY2005–19$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$3,040,933 · 6
By mechanism
P30$1,467,428 · 1
M01$680,750 · 3
P01$610,855 · 1
R21$281,900 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Douglas Hamilton Smith$26,977,456
- Stephen G Emerson$28,932,839
- Thomas A. Wadden$34,016,838
- William M Lee$5,600,205
- Robert S Moreland$5,026,904
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHuman Therapy EvaluationClinical Trial Phase INeoplasm /Cancer ChemotherapyGrantCancer Center Support GrantFutureCostCancer CenterData ManagementFundingImaging ModalityDoxorubicinCollaborationsClinical TrialsAngiogenesis InhibitionDesignComplexCorrelative StudyBiologicalCell TherapyFoundationsIndustry
Grant awards (25)
EARLY PHASE CLINICAL RESEARCH SUPPORT (Core 14)$7,211
P30 · FY2019 · CA · contact PI
EARLY PHASE CLINICAL RESEARCH SUPPORT (Core 14)$5,767
P30 · FY2019 · CA · contact PI
EARLY PHASE CLINICAL RESEARCH SUPPORT (Core 14)$3,626
P30 · FY2019 · CA · contact PI
EARLY PHASE CLINICAL RESEARCH SUPPORT (Core 14)$1,106
P30 · FY2019 · CA · contact PI
EARLY PHASE CLINICAL RESEARCH SUPPORT (Core 14)$424,808
P30 · FY2018 · CA · contact PI
EARLY PHASE CLINICAL RESEARCH SUPPORT (Core 14)$9,404
P30 · FY2018 · CA · contact PI
EARLY PHASE CLINICAL RESEARCH SUPPORT (Core 14)$2,510
P30 · FY2018 · CA · contact PI
EARLY PHASE CLINICAL RESEARCH SUPPORT (Core 14)$2,143
P30 · FY2018 · CA · contact PI
EARLY PHASE CLINICAL RESEARCH SUPPORT (Core 14)$506,162
P30 · FY2017 · CA · contact PI
EARLY PHASE CLINICAL RESEARCH SUPPORT (Core 14)$504,691
P30 · FY2016 · CA · contact PI
UPCC 09803: CARDIOVASCULAR RISK IN TESTICULAR CANCER SURVIVORS$7,158
M01 · FY2005 · RR
Cardiovascular Risk in Testicular Cancer Survivors$140,950
R21 · FY2004 · CA
Cardiovascular Risk in Testicular Cancer Survivors$140,950
R21 · FY2003 · CA
PHASE I TRIAL OF ADENOVIRUS GA733-2 VACCINE FOR COLORECTAL CANCER$228,401
P01 · FY2002 · CA
UPCC 7897 WEEKLY LIPOSOME ENCAPSULATED DOXORUBICIN (LED) IN HORMONE$124,146
M01 · FY2002 · RR
PHASE I TRIAL OF ADENOVIRUS GA733-2 VACCINE FOR COLORECTAL CANCER$228,401
P01 · FY2001 · CA
UPCC 7897 WEEKLY LIPOSOME ENCAPSULATED DOXORUBICIN (LED) IN HORMONE$124,146
M01 · FY2001 · RR
UPCC 7897 WEEKLY LIPOSOME ENCAPSULATED DOXORUBICIN (LED) IN HORMONE$0
M01 · FY2001 · RR
PHASE I STUDY--LIPOSOME ENCAPSULATED DOXORUBICIN$187,536
M01 · FY2000 · RR
PHASE I STUDY--LIPOSOME ENCAPSULATED DOXORUBICIN$187,536
M01 · FY2000 · RR
PHASE I TRIAL OF ADENOVIRUS GA733-2 VACCINE FOR COLORECTAL CANCER$154,053
P01 · FY2000 · CA
UPCC 7897 WEEKLY LIPOSOME ENCAPSULATED DOXORUBICIN (LED) IN HORMONE$25,114
M01 · FY2000 · RR
PHASE I STUDY--LIPOSOME ENCAPSULATED DOXORUBICIN$25,114
M01 · FY2000 · RR
UPCC 7897 WEEKLY LIPOSOME ENCAPSULATED DOXORUBICIN (LED) IN HORMONE$0
M01 · FY2000 · RR
UPCC 7897 WEEKLY LIPOSOME ENCAPSULATED DOXORUBICIN (LED) IN HORMONE$0
M01 · FY2000 · RR